FibroGen Inc
FGEN
ISIN null / Valor 25953994
FibroGen Inc
UMushroom community rating:
About company
FibroGen is a biopharmaceutical company that discovers, develops and commercializes therapies focused primarily on anemia, fibrotic diseases and oncology; its most advanced programs include an oral hypoxia‑inducible factor (HIF) prolyl hydroxylase inhibitor for anemia associated with chronic kidney disease and an anti‑connective tissue growth factor (CTGF) antibody being developed for fibrotic disorders and select cancers. The company advances candidates through clinical trials, leverages partnerships with larger pharmaceutical companies for development and global commercialization, and generates revenue through product sales, milestone and royalty arrangements, and collaborative agreements while maintaining a pipeline of earlier‑stage programs aimed at addressing unmet needs in hematology, fibrosis and oncology.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
27 M
Market cap (USD)
6,835
Daily traded volume (Shares)
0.59 / 0.5133
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
